BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22689689)

  • 1. Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.
    Pascal V; Laffleur B; Debin A; Cuvillier A; van Egmond M; Drocourt D; Imbertie L; Pangault C; Tarte K; Tiraby G; Cogné M
    Haematologica; 2012 Nov; 97(11):1686-94. PubMed ID: 22689689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
    Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
    J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies.
    Evers M; Ten Broeke T; Jansen JHM; Nederend M; Hamdan F; Reiding KR; Meyer S; Moerer P; Brinkman I; Rösner T; Lebbink RJ; Valerius T; Leusen JHW
    MAbs; 2020; 12(1):1795505. PubMed ID: 32744145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.
    Lohse S; Brunke C; Derer S; Peipp M; Boross P; Kellner C; Beyer T; Dechant M; van der Winkel JG; Leusen JH; Valerius T
    J Biol Chem; 2012 Jul; 287(30):25139-50. PubMed ID: 22679018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
    Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
    Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
    Brandsma AM; Ten Broeke T; Nederend M; Meulenbroek LA; van Tetering G; Meyer S; Jansen JH; Beltrán Buitrago MA; Nagelkerke SQ; Németh I; Ubink R; Rouwendal G; Lohse S; Valerius T; Leusen JH; Boross P
    Cancer Immunol Res; 2015 Dec; 3(12):1316-24. PubMed ID: 26407589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.
    Brandsma AM; Bondza S; Evers M; Koutstaal R; Nederend M; Jansen JHM; Rösner T; Valerius T; Leusen JHW; Ten Broeke T
    Front Immunol; 2019; 10():704. PubMed ID: 31031746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
    Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
    Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin A-mediated protection against Bordetella pertussis infection.
    Hellwig SM; van Spriel AB; Schellekens JF; Mooi FR; van de Winkel JG
    Infect Immun; 2001 Aug; 69(8):4846-50. PubMed ID: 11447159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
    Dechant M; Vidarsson G; Stockmeyer B; Repp R; Glennie MJ; Gramatzki M; van De Winkel JG; Valerius T
    Blood; 2002 Dec; 100(13):4574-80. PubMed ID: 12393717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4.
    van der Steen L; Tuk CW; Bakema JE; Kooij G; Reijerkerk A; Vidarsson G; Bouma G; Kraal G; de Vries HE; Beelen RH; van Egmond M
    Gastroenterology; 2009 Dec; 137(6):2018-29.e1-3. PubMed ID: 19555692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor.
    Dechant M; Beyer T; Schneider-Merck T; Weisner W; Peipp M; van de Winkel JG; Valerius T
    J Immunol; 2007 Sep; 179(5):2936-43. PubMed ID: 17709508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19).
    Shi J; McIntosh RS; Adame-Gallegos J; Dehal PK; van Egmond M; van de Winkel J; Draper SJ; Forbes EK; Corran PH; Holder AA; Woof JM; Pleass RJ
    BMC Biotechnol; 2011 Jul; 11():77. PubMed ID: 21781305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgA EGFR antibodies mediate tumour killing in vivo.
    Boross P; Lohse S; Nederend M; Jansen JH; van Tetering G; Dechant M; Peipp M; Royle L; Liew LP; Boon L; van Rooijen N; Bleeker WK; Parren PW; van de Winkel JG; Valerius T; Leusen JH
    EMBO Mol Med; 2013 Aug; 5(8):1213-26. PubMed ID: 23918228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors.
    Otten MA; Rudolph E; Dechant M; Tuk CW; Reijmers RM; Beelen RH; van de Winkel JG; van Egmond M
    J Immunol; 2005 May; 174(9):5472-80. PubMed ID: 15843545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).
    van Egmond M; van Spriel AB; Vermeulen H; Huls G; van Garderen E; van de Winkel JG
    Cancer Res; 2001 May; 61(10):4055-60. PubMed ID: 11358825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
    Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
    Front Immunol; 2018; 9():244. PubMed ID: 29651286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
    Engelberts PJ; Voorhorst M; Schuurman J; van Meerten T; Bakker JM; Vink T; Mackus WJ; Breij EC; Derer S; Valerius T; van de Winkel JG; Parren PW; Beurskens FJ
    J Immunol; 2016 Dec; 197(12):4829-4837. PubMed ID: 27807190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells.
    Leung JCK; Tsang AWL; Chan DTM; Lai KN
    J Am Soc Nephrol; 2000 Feb; 11(2):241-249. PubMed ID: 10665931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.